Clinical Trial Update: A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating 3HP-2827 in adults with solid tumors harboring FGFR2 alterations; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors with Fgfr2 Alterations

Drugs mentioned

• 3HP-2827 (3HP-2827)

Snippet

Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd. | Conditions: Solid Tumors With FGFR2 Alterations, Adult | Phase 1, Phase 2 | Status: RECRUITING